21 nov: Draghi ser fortsat behov for støtte for at nå inflationsmål - NY
22 nov: Novo: USA godkender kombinationsmidlet Xultophy
22-11-2016 01:38:22

The U.S. FDA approves Soliqua(TM) 100/33 for the treatment of adults with type 2 diabetes

Relateret indhold
09 aug - 
KORR: Zealand Pharma er nu dobbeltnoteret i Danmark og ..
09 aug - 
Zealand Pharma er nu dobbeltnoteret i Danmark og USA
09 aug - 
Zealand vil rejse en halv milliard ved børsnotering i U..
Relateret debat
17:09 - 
Hvad betyder "Not FDA Approved for Orphan Indication"? ..
16:44 - 
hanfrank du må forstå du tager fejl igen. 🤔
16:41 - 
"Begge", vi taler nu ikke om "begge", MENA - vi taler o..

Company announcement - No. 46 / 2016

 

The U.S. FDA approves Soliqua(TM) 100/33 for the treatment of adults with type 2 diabetes

  • FDA approval triggers a $25 million milestone payment and double-digit percentage royalties of net sales of Soliqua(TM) to Zealand

     

  • Sanofi plans to make Soliqua(TM) available in U.S. retail pharmacies in January 2017

  • Zealand management will host a teleconference on Tuesday 22 November at 4pm CET

Copenhagen, 22 November 2016 - Zealand Pharma (Zealand) announced today that Sanofi has received  U.S. Food and Drug Administration (FDA) approval for Soliqua(TM) 100/33 (insulin glargline and lixisenatide injection) 100 Units/mL and 33 mcg/mL for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide (AdlyxinTM).

SoliquaTM 100/33 will be delivered in a single pre-filled pen for once-daily dosing covering 15 to 60 Units of insulin glargine 100 Units/mL and 5 to 20 mcg of lixisenatide using SoloSTAR® technology, the most frequently used disposable insulin injection pen platform in the world.[1] SoliquaTM 100/33 will be available in U.S. retail pharmacies in January 2017.

Britt Meelby Jensen, President and Chief Executive Officer of Zealand commented:

 "I am very excited about FDA's approval of Soliqua(TM). The fixed-ratio combination of Lantus® and lixisenatide is a new drug, that has proven to outperform its individual components. The U.S. approval of Soliqua(TM) comes only 10 days after CHMP recommended approval of Suliqua(TM) in the EU, making November 2016 one of the most important months in the history of Zealand. Together with lixisenatide, which was approved in the U.S. in July this year under the brand name Adlyxin(TM), we expect substantial revenue growth in the years to come. This gives us the financial strength to deliver on our strategy to develop our own product candidates, glepaglutide and dasiglucagon all the way to registration".

Elias Zerhouni, M.D., President, Global R&D, Sanofi commented:

"Sanofi continues to be a pioneer in developing diabetes therapies and in bringing forward new treatment options for the approximately 50 percent of patients whose blood sugar levels remain uncontrolled on daily basal insulin. Soliqua 100/33 is an alternate new approach that can help adults living with type 2 diabetes uncontrolled on basal insulin or lixisenatide to reach their treatment goal.

"

SoliquaTM 100/33 is the combination of Lantus® (insulin glargine 100 Units/mL) and lixisenatide, a GLP-1 receptor agonist, in a once-daily injection, studied in a Phase 3 program of more than 1,900 patients. In an insulin intensification study, SoliquaTM 100/33 showed better HbA1c (average blood sugar over time) lowering versus Lantus® with a majority of the 736 patients (55% vs. 30%) achieving the American Diabetes Association target of less than 7% at 30 weeks. Patients treated with SoliquaTM 100/33 experienced similar rates of documented (<70 mg/dL) hypoglycemia compared to Lantus®-treated patients.

CHMP positive opinion recommending Suliqua

TM

in the EU

Earlier in November, Sanofi received a positive opinion from the Committee for Medicinal Product for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of Suliqua(TM) (brand name in Europe). A formal decision by the European Commission is expected in the coming months. Once approved, Sanofi will make Suliqua(TM) available in the EU in two pre-filled SoloSTAR® pens (10-40 SoloSTAR® pen and 30-60 SoloSTAR® pen).

Conference call on Tuesday, 22 November 2016 at 4 pm CET / 10 am EDT

Zealand's senior management will host a conference call Tuesday, 22 November at 4 pm CET to give an update on the implications for Zealand. Participating in the call will be Britt Meelby Jensen, President and Chief Executive Officer, Mats Blom, SVP and Chief Financial Officer and Adam Steensberg, SVP and Chief Medical and Development Officer. The presentation will be followed by a Q&A session.

The conference call will be conducted in English and the dial-in numbers are:

DK standard access             +45 32 71 16 60

UK and international            +44 (0) 20 3427 1919

U.S. (free dial-in)                 +1 646 254 3362

Kindly inform the operator of the following passcode: "Zealand Pharma" or 4119215.  

A live audio webcast of the call including an accompanying slide presentation will be available via the following link, http://edge.media-server.com/m/p/ykcwu3fn accessible also from the company's website (www.zealandpharma.com). Participants are advised to register for the webcast approximately 10 minutes before the start.

A replay of the event will be made available from the Investor section of Zealand's website following the call.

Terms of the license agreement with Sanofi

Under the terms of the license agreement between Sanofi and Zealand, which covers lixisenatide and any combination product that includes lixisenatide, Sanofi is responsible for all development and commercialization including the financing.

The approval of Soliqua(TM) by the U.S. FDA triggers a milestone payment of $25 million to Zealand from Sanofi. Zealand is eligible to receive remaining milestone payments of up to $110 million as well as royalties on global sales. Royalties correspond to tiered, low double-digit percentages of Sanofi's global sales of AdlyxinTM/Lyxumia® plus a fixed low double-digit percentage of global net sales of SoliquaTM/SuliquaTM.

*****

For further information, please contact:

Britt Meelby Jensen,

President and Chief Executive Officer

Tel.: +45 51 67 61 28, e-mail:

bmj@zealandpharma.com

Mats Blom,

Senior Vice President, Chief Financial Officer

Tel.: +45

31 53 79 73

, e-mail:

mabl@zealandpharma.com

 

About Soliqua

(TM)

Soliqua(TM) is a once-daily, titratable fixed-ratio combination of lixisenatide GLP-1 receptor agonist (Adlyxin(TM)/Lyxumia®) and basal insulin glargine 100 units/ml (Lantus®) for the treatment of adults with type 2 diabetes.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under licence collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of proprietary product candidates which primarily target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia® outside the United States and approved as Adlyxin(TM) in the United States. Lixisenatide has been developed in a fixed-ratio combination with basal insulin glargine (Lantus®) and is approved as Soliqua(TM) in the United States, and in Europe a CHMP positive opinion recommendation was given on 11 November. Suliqua(TM) is the brand name in Europe.

Zealand's proprietary pipeline includes: Dasiglucagon* (ZP4207) (single-dose rescue treatment) for acute, severe hypoglycaemia (Phase II); Glepaglutide* (ZP1848) for short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) (multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycaemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and Glepaglutide are proposed International Nonproprietary Names (pINN).


[1]

Data on file: IMS Q_Global Q4/2015, V.Kircher

46-16_1122 US approval of SoliquaTM


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via Globenewswire

Vedhæftet fil: 771449.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
14:18
ZEAL
Jeg mener kun jeg har set at de har ansøgt men nu ser det ud til at de har fået svar.   Zealand Phar..
8
14 aug
ZEAL
Tænk Hvad i 2 ikke kunne udrette hvis i blot brugte jeres tid på noget fornuftigt?
8
14:30
ZEAL
Du kan omvendt argumentere at der er har været en "rabat" på at der var en frygt knyttet til at man ..
3
14 aug
ZEAL
Det hedder stadig ikek en IPO, for det hedder det kun foerste gang et firma gaar paa boersen....... ..
3
12 aug
ZEAL
At Soliqus er markedsleder med kombinationsproduktet Soliqua kan ingen vist betvivle.    Zealand Pha..
3
12 aug
ZEAL
Soliqua er stadig markedsleder med kombinationsprodukterne fra Novo og Sanofi selvom godkendelsen af..
3
10 aug
ZEAL
Prospekt i dag, måske med afsløring af forventninger til indtjening fra Adlyxin, Lyxumia og Soliqua ..
3
14 aug
ZEAL
Det var ikke det som vi havde håbet på, men nu salget af Soliqua lader vente på sig var der nok ikke..
2
14 aug
ZEAL
I er blevet udvandet så det driver. 🤔 Aktie rabat og 50 millioner i omkostninger. Synes i er blevet..
2
14 aug
ZEAL
Company announcement - No. 35/2017     Zealand Pharma A/S has today registered a capital increase o..
2

Coloplast/CEO: Har underskrevet ny VA-kontrakt på trods af fejl

16-08-2017 14:33:48
En fejl i administrationen af kontrakten med det amerikanske veteranministerium, U.S Department of Veterans Affairs, har betydet, at det danske medicoselskab Coloplast vurderer, at det skal tilbagebetale 90 mio. kr. til ministeriet.Selskabets oplyste om engangsbeløbet i regnskabet for tredje kvartal af det forskudte regnskabsår 2016/2017, der blev fremlagt onsdag ved middagstid, og her fremgik det..

Aktier/middag: Mærsk og Carlsberg deles om top og bund i grønt C20

16-08-2017 11:33:01
Med plusser til størstedelen af de danske eliteaktier ligger C20 Cap-indekset onsdag middag i positivt terræn, og med til at trække op er Mærsk-aktierne efter koncernens regnskab. Omvendt bliver Carlsberg straffet for sit.Samlet går C20 Cap-indekset frem med 0,3 pct. til 1170,82, og dermed følger det danske eliteindeks trenden i resten af Europa, hvor de fleste aktieindeks ligeledes noterer stigni..

Aktier/tendens: Regnskaber i centrum for udvikling i C20 Cap

16-08-2017 08:36:09
Der er ikke meget påvirkning eller inspiration at hente fra udlandet for de danske investorer onsdag, og dagens udvikling i C20 Cap-indekset vil sandsynligvis blive bestemt af dagens regnskaber fra nogle af indekset tunge selskaber med A.P. Møller-Mærsk i spidsen.C20 Cap-indekset lukkede tirsdag med et fald på 0,1 pct. til 1167,07.De amerikanske aktier lukkede tirsdag med små udsving tæt på nulpun..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas/Sydbank: Sætter tungt aftryk på konkurrencepræget marked - NY
2
NNIT/CEO: Vi stopper ikke op og håber på Novo Nordisk
3
Spar Nord opjusterer og ændrer udbyttepolitik
4
Vestas bekræfter ordre på 424 MW i Mexico
5
Danske rederier har nået bunden - citat

Relaterede aktiekurser

Zealand Pharma A/S 115,00 1,3% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
16. august 2017 17:13:28
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170808.1 - EUROWEB2 - 2017-08-16 17:13:28 - 2017-08-16 17:13:28 - 1 - Website: OKAY